AZR · XBRL financial data

Adial Pharmaceuticals financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AZR's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	430	207	264*	1,013	1,032	731*	747	732	521	619*	433	440
General and administrative	1,047	1,151	1,519*	1,275	1,180	1,210*	1,520	1,150	1,243	1,266*	1,569	5,400
Total operating expenses	1,477	1,358	1,784*	2,287	2,211	1,941*	2,267	1,883	1,764	1,885*	2,001	52,025
Other operating income (expense)	—	—	—	—	year only	year only	—	—	—	—	—	—
Operating income (loss)	(1,477)	(1,358)	(1,784)*	(2,287)	(2,211)	(1,941)*	(2,267)	(1,883)	(1,764)	(1,885)*	(2,001)	(52,025)
Interest income	19	10	11*	51	51	54*	35	24	48	43*	47	58
Other income (expense)	—	—	62*	(0)*	0*	(75)*	166	(1)	(1)	(0)*	—	—
Net income (loss)	1,088	(1,385)	(1,920)*	(2,458)	(2,192)	(2,071)*	(2,229)	(1,959)	(1,794)	(1,996)*	(2,022)	(51,989)
Earnings per share, basic USD per share	0.96	(1.18)	—	(0.59)	(0.38)	—	(0.34)	(0.18)	(0.08)	—	(1.48)	(11.25)
Earnings per share, diluted USD per share	0.96	(1.18)	—	(0.59)	(0.38)	—	(0.34)	(0.18)	(0.08)	—	(1.48)	(11.25)
Weighted average shares, basic thousands of shares	—	—	—	—	5,836	—	262	425	22,171	—	1,370	4,622
Weighted average shares, diluted thousands of shares	1,131	1,179	—	4,183	5,836	—	6,540	10,623	22,171	—	1,370	4,622

† Share count changed about 1/17 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (AZR's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,218	316	2,827	3,288	5,204	3,751	2,366	5,915	4,606	5,881	4,584	28,712
Prepaid and other current assets	91	470	372	189	410	308	263	164	408	300	219	133
Total current assets	2,047	1,135	3,199	3,823	5,619	4,059	2,629	6,079	5,014	6,181	4,803	28,845
Total assets	3,779	2,867	4,737	4,949	6,713	5,044	3,451	6,802	5,660	6,673	5,227	29,089
Accounts payable	112	82	103	317	318	250	532	671	556	655	574	2,624
Accrued liabilities	324	409	478	335	501	677	759	540	598	742	937	2,497
Total current liabilities	462	528	653	672	829	976	1,324	1,211	1,155	1,397	1,510	5,121
Total liabilities	462	528	653	672	829	976	1,324	1,211	1,155	1,397	1,510	28,933
Accumulated deficit	(65,493)	(66,878)	(68,798)	(77,733)	(79,925)	(81,995)	(84,224)	(86,183)	(87,976)	(89,972)	(91,995)	(143,984)
Total stockholders' equity	3,317	2,339	4,084	4,277	5,884	4,068	2,127	5,591	4,505	5,276	3,717	(38,377)
Total liabilities and equity	3,779	2,867	4,737	4,949	6,713	5,044	3,451	6,802	5,660	6,673	5,227	29,089
Common shares outstanding (cover page) thousands of shares	1,218	1,218	4,055	6,403	6,406	6,575	7,901	21,828	23,988	1,428	2,144	2,626

† Share count changed about 1/17 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (AZR's year ends in late December)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	1,088	(1,385)	(1,920)*	(2,458)	(2,192)	(2,071)*	(2,229)	(1,959)	(1,794)	(1,996)*	(2,022)	(51,989)
Stock-based compensation	738*	268*	281*	202*	188*	180*	237	124*	147*	168*	148	137*
Net cash from operating activities	(1,894)*	(1,391)*	(1,223)*	(2,148)*	(1,694)*	(1,454)*	(1,585)	(1,749)*	(1,833)*	(1,325)*	(1,612)	(6,363)*
Net cash from investing activities	—	350*	350*	—	—	—	150	0*	0*	0*	—	—
Proceeds from issuing common stock	—	140*	0*	—	3,610*	0*	51	3,077*	478*	54*	315	850*
Proceeds from issuing equity	—	—	—	—	—	0*	—	—	—	2,600*	300	—
Share repurchases	—	—	0*	—	—	—	—	—	—	—	—	—
Net cash from financing activities	0*	139*	3,384*	411*	3,610*	0*	51	5,298*	525*	2,599*	315	25,209*

† Share count changed about 1/17 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.